PBM - PRISM Mid-Day Movers: Mental Health Momentum and Biotech Setbacks Define Market Sentiment

2025-08-01 13:01:29 ET

BioXcel Rallies 27% on Expanded Schizophrenia Study and Positive FDA Interaction
BioXcel Therapeutics, Inc. ( BTAI ) surged 27.48% to lead the PRISM Emerging Mental Health Index after announcing a pivotal update to its TRANQUILITY III trial evaluating BXCL501 in schizophrenia-related agitation . The FDA supported the company's amended protocol to incorporate both bipolar disorder and schizophrenia cohorts under a single Phase 3 study, streamlining regulatory efforts and expanding market potential. BioXcel also reaffirmed plans to submit a supplemental NDA in 2026.

NeuroSense Falls 29% Despite Advancing Toward Pivotal ALS Trial
NeuroSense Therapeutics Ltd. ( NRSN ) dropped 29.45%, weighing heavily on the PRISM Emerging Biotech Index , despite announcing meaningful progress toward a pivotal Phase 3 trial of its ALS drug candidate PrimeC . While the company showcased promising data from its PARADIGM Phase 2b trial, highlighting a 74% improvement in overall survival and 40% slower functional decline, investors reacted negatively to lingering financial concerns, ongoing partnership negotiations, and the $4.7 million operating loss for H1 2025. A share price retreat followed recent dilution from private placements, despite their drug's advancing clinical profile.

Other PRISM Mid-Day Movers:
? Mullen Automotive, Inc. ( MULN ) down 29.13%
? Psyence Biomedical Ltd. ( PBM ) down 29.22%
? 374Water, Inc. ( SCWO ) down 18.63%
? Riot Platforms, Inc. ( RIOT ) down 16.14%

The post PRISM Mid-Day Movers: Mental Health Momentum and Biotech Setbacks Define Market Sentiment appeared first on PRISM MarketView .

COMTEX_467715897/2927/2025-08-01T12:01:29